Clinical trial Recruiting at 1 site Phase2; Phase3 Interventional Ages 18 to 60

Amitriptyline versus Trifluoperazine for functional dyspepsia

Official title: Effect of Amitriptyline and Trifluoperazine on Patients With Functional Dyspepsia

Run by Dhaka Medical College · NCT07008235 · Data updated 2026-11-12

This trial will test whether adding low‑dose amitriptyline or trifluoperazine to standard treatment helps adults with functional dyspepsia feel better over 8 weeks.

Quick facts

PhasePhase2; Phase3
Study typeInterventional
Ages18 Years to 60 Years
SexAll
Enrollment120 (estimated)
SponsorDhaka Medical College
Academic / other
Locations1 site (Dhaka)
StatusRecruiting
StartedJuly 1, 2025
Main results expectedJune 2026
Study endsJune 2026
Registry record updatedMay 7, 2026
Trial IDNCT07008235 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18 or older with symptoms meeting Rome IV criteria for functional dyspepsia who can give informed consent and attend study visits are ideal candidates.

Probably not a fit

Patients with structural upper GI disease, major medical or psychiatric comorbidities, current use of antidepressants or antipsychotics, prior hypersensitivity to the study drugs, or needing contraindicated co‑medications are unlikely to benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults with functional dyspepsia will be assigned to one of three groups: amitriptyline 10 mg at night plus standard first‑line therapy, trifluoperazine 1 mg twice daily plus standard therapy, or standard therapy alone for 8 weeks. Symptom changes and patient‑reported adverse events will be recorded to compare benefit and safety between the groups. After the 8‑week treatment period, all groups will be followed according to the protocol described by the investigators. The trial focuses on symptomatic improvement using established dyspepsia criteria and routine safety monitoring.

Why it matters

Potential benefit: If successful, adding one of these low‑dose neuromodulators could reduce dyspepsia symptoms and improve daily comfort for patients.

How similar studies have gone: Low‑dose tricyclics such as amitriptyline have shown benefit in some functional GI disorder studies, while trifluoperazine is less well studied for functional dyspepsia.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age 18 years or more
* Patients with symptoms of dyspepsia for duration consisted with ROME IV criteria
* Patients who are willing to sign informed written consent

Exclusion Criteria:

* Structural lesion in Upper GI endoscopy and/or positive CLO test
* Patients scoring 1 or 2 on the 5-point Likert scale for all four dyspepsia symptoms
* History of malignancy, significant liver and biliary tract disease, hypertension, diabetes mellitus, chronic kidney disease, thyroid disorder, major psychiatric disorders
* Previous history of gastrointestinal surgery
* Patients those have to take any drug for other medical condition that may cause dyspepsia, can interfere or whose co-prescription is contraindicated with amitriptyline or trifluoperazine
* Any patient with ongoing treatment with antidepressants or antipsychotics
* Any history of hypersensitivity, adverse effect, or ineffectiveness with amitriptyline or trifluoperazine
* Patients for whom Amitriptyline and Trifluoperazine are contraindicated
* Elderly patients\> 60 years
* Pregnancy and breastfeeding

Where it's running

  • Dhaka Medical College
    Dhaka, Bangladesh
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.